ReviewTherapeutic advances in infectious disease2017

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Biswadeep Das et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.